iCAD to highlight AI for tomosynthesis at ECR
iCAD plans to highlight its artificial intelligence (AI) software for digital...Read more on AuntMinnie.comRelated Reading: iCAD touts clinical results with Xoft Axxent brachytherapy iCAD highlights study results of DBT software iCAD touts study on radiation therapy savings iCAD scores Chinese OK for balloon applicators iCAD to highlight Xoft clinical results at AAPM
Conclusions: Unlike past results, gemcitabine and cisplatin appear to be tolerable, efficient and feasible when combined with conformal radiotherapy.
Ricke et al. reported their findings on the efficacy and safety of selective internal radiation therapy (SIRT) with resin yttrium-90 (90Y) microspheres (SIR-Spheres®, Sirtex) in combination with sorafenib compared to sorafenib treatment alone. This clinical trial with a superiority design, also known as t he SORAMIC study, was performed in patients with intermediate to advanced hepatocellular carcinoma (HCC). No overall survival (OS) benefit was found when adding SIRT to sorafenib treatment. In the ‘intention-to-treat’ population, median OS was 12.1 months in the SIRT plus sorafenib group vs.
Radiation therapy remains an essential component of cancer therapy for millions of patients annually in the United States and globally. Radiation therapy involves the focal deposition of ionizing radiation (IR) to the tumor and surrounding at-risk tissue compartments such as regional lymph nodes. The most common treatment approaches include external beam radiation therapy (EBRT) using high-energy photons, electrons, or protons, as well as brachytherapy and radionuclide therapy. Significant technical advances in EBRT and diagnostic imaging over the past several decades have enabled more localized and precise dose deposition...
CONCLUSION: PDR salvage brachytherapy in local recurrent previously irradiated prostate cancer is efficient with low late toxicity. Salvage-brachytherapy represents a valuable therapeutic option for the treatment of previously irradiated locally recurrent prostate cancer. PMID: 32593646 [PubMed - as supplied by publisher]
Alongside radical prostatectomy, radiation therapy is an effective treatment modality for prostate cancer patients irrespective of risk group. Nevertheless, a considerable number of these patients are faced with isolated local failure of prostate cancer after radiation therapy with curative intent. Up to 10% of patients with a low-risk, 10-20% with an intermediate-risk and up to 30-37% with high-risk tumors will suffer local recurrence during follow-up [1 –4]. Thus, the possibility of an effective local salvage therapy is of paramount importance for curative therapy of a prostate cancer recurrence.
Intraoperative radiation therapy (IORT), a form of accelerated partial breast irradiation (APBI), is an appealing alternative to postoperative whole breast irradiation for early-stage breast cancer. The purpose of this study was to examine the toxicity and cosmetic outcomes of patients treated with a novel form of breast IORT (precision breast IORT; PB-IORT), that delivers a targeted, higher dose of radiation than conventional IORT.
(Medical College of Georgia at Augusta University) The sugar coating on cancer cells helps them thrive, and a new study indicates patients with cervical cancer who make antibodies to those sugars appear to do better when they also receive internal radiation therapy.
lland Selective internal radiation therapy (SIRT) of hepatocellular carcinoma (HCC) has been used for many years, usually without any specific dosimetry endpoint. Despite good clinical results in early phase studies or in cohort studies, three randomized trials in locally advanced HCC available failed to demonstrate any improvement of overall overall survival (OS) in comparison with sorafenib. In recent years, many studies have evaluated the dosimetry of SIRT using either a simulation-based dosimetry (macroaggregated albumin (MAA)-based) or a post-therapy-based one (90Y-based). The goal of this review is to present the...
(American Society for Radiation Oncology) A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline--ASTRO's first for cervical cancer--outlines indications and best practices for external beam radiation therapy and brachytherapy in the postoperative and definitive settings. Recommendations also address other treatments including chemotherapy and surgery when used in combination with radiation. The guideline is published online in Practical Radiation Oncology.
ConclusionsMaximal reduction of the rectal dose seems very important to prevent serious rectal hemorrhage. In addition, we should consider the risk of rectal toxicities in patients with abnormalities in the rectal mucosa, especially hemorrhoids.